14 completed, 1 recruiting, 1 terminated, 1 unknown. 11 Phase 2, 7 Phase 1, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 9, Recruiting 1, Unknown 1 |
| Phase 1 | 7 | Completed 7 |
| Phase 3 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Not applicable | 1 | Terminated 1 |
Follow vosaroxin: new trials by email Literature Review of vosaroxin trials Research Report on vosaroxin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 Vosaroxin, Azacitidine - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) | Phase 2 | Completed | University of Ulm | 9 | 2018-04-19 | 2020-10-28 |
| Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia Cytarabine, Vosaroxin - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 42 | 2016-03-01 | 2025-04-15 |
| Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML Vosaroxin and Cytarabine - Leukemia, Myeloid, Acute | Not applicable | Terminated | Hamid Sayar | 2 | 2015-10-20 | 2017-09-20 |
| Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR Idarubicin, Daunorubicin, HD Cytarabine - Acute Myeloid Leukemia (AML) | Phase 2 / Phase 3 | Recruiting | University Hospital, Angers | 3100 | 2015-01-01 | 2026-07-17 |
| Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations Arm A Mylotarg plus DA Versus CPX-351, Arm B Vosaroxin and Decitabine, Arm D Small molecule or Not - Acute Myeloid Leukaemia, Myelodysplastic Syndrome | Phase 2 / Phase 3 | Unknown | Cardiff University | 1600 | 2014-10-30 | 2020-01-23 |
| Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes vosaroxin, Azacitidine - Myelodysplastic Syndromes | Phase 1 | Completed | Washington University School of Medicine | 35 | 2013-11-22 | 2024-05-02 |
| Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy Vosaroxin - Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 10 | 2013-10-25 | 2019-02-19 |
| Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Vosaroxin, Decitabine - Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2013-07-18 | 2022-02-09 |
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML vosaroxin + cytarabine, placebo + cytarabine - Acute Myeloid Leukemia | Phase 3 | Completed | Sunesis Pharmaceuticals | 711 | 2010-12-17 | 2018-08-22 |
| Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia vosaroxin - Leukemia, Acute Disease | Phase 2 | Completed | Sunesis Pharmaceuticals | 113 | 2008-05-15 | 2017-06-28 |
| Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans Voreloxin injection and cytarabine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Sunesis Pharmaceuticals | 110 | 2007-10-06 | 2018-01-09 |
| Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer Voreloxin Injection - Epithelial Ovarian Cancer | Phase 2 | Completed | Sunesis Pharmaceuticals | 183 | 2006-12-20 | 2017-07-27 |
| Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer SNS-595 - Carcinoma, Small Cell, Small Cell Lung Cancer | Phase 2 | Completed | Sunesis Pharmaceuticals | 55 | 2006-02-01 | 2018-07-26 |
| Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC SNS-595 Injection - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Sunesis Pharmaceuticals | 31 | 2005-12-27 | 2018-09-24 |
| Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies Vosaroxin - Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute | Phase 1 | Completed | Sunesis Pharmaceuticals | 75 | 2005-11-14 | 2017-03-30 |
| Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors SNS-595 - Neoplasms | Phase 1 | Completed | Sunesis Pharmaceuticals | 2004-10-01 | 2007-05-10 | |
| Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors. SNS-595 - Neoplasms | Phase 1 | Completed | Sunesis Pharmaceuticals | 2004-06-01 | 2007-05-10 |
Leukemia, Myeloid, Acute (10) · Neoplasms (9) · Leukemia (5) · Myelodysplastic Syndromes (5) · Carcinoma (3) · Hematologic Diseases (2) · Acute Disease (1) · Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Small Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Chronic (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Sunesis Pharmaceuticals (9) · Cardiff University (1) · Hamid Sayar (1) · M.D. Anderson Cancer Center (1) · University Hospital, Angers (1) · University of Ulm (1) · Vanderbilt-Ingram Cancer Center (1) · Washington University School of Medicine (1) · Weill Medical College of Cornell University (1)
United States (14) · Canada (3) · France (2) · Germany (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · Hungary (1) · Italy (1) · New Zealand (1) · Poland (1) · South Korea (1)
Daniel C. Adelman, MD (2) · Glenn Michelson, MD (2) · Adam Craig, MD (1) · Craig Berman, MD (1) · Gail Roboz, MD (1) · Hamid Sayar, MD (1) · Linda Neuman, MD (1) · Meagan Jacoby, M.D., Ph.D. (1) · Michael Savona, MD (1) · Naval Daver, MD (1) · Nigel Russell, Prof (1) · Sanjay Mohan, MD (1)
PMID 25381131, PMID 25403830, PMID 26234174, PMID 28729302, PMID 40552969, PMID 41237344, PMID 42166362
P30CA068485 (1)